<DOC>
	<DOCNO>NCT01013116</DOCNO>
	<brief_summary>The objective study evaluate efficacy safety specific subcutaneous immunotherapy modify allergen extract .</brief_summary>
	<brief_title>Evaluation Efficacy Safety Specific Immunotherapy With Modified Allergen Extracts House Dust Mites</brief_title>
	<detailed_description />
	<mesh_term>Rhinitis , Allergic</mesh_term>
	<mesh_term>Rhinitis</mesh_term>
	<criteria>Positive history perennial allergic rhinitis due house dust mite Positive screen skin prick test ( wheal diameter &gt; 3 mm ) Compliance ability patient complete Diary Card selfevaluating symptom antisymptomatic medication Signed date patient´s Informed Consent , Previous immunotherapy mite extract within last 3 year , Simultaneous participation clinical trial , Other reason contraindicate inclusion trial accord investigator´s estimation ( e.g . poor compliance ) , Autoimmune disorder , Severe chronic inflammatory disease , Malignancy , Alcohol abuse , Existing intend pregnancy , lactation and/or lack adequate contraceptive protection , Treatment betablockers ( incl . local application ) and/or contraindicate drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>